Literature DB >> 21908288

In vitro antimicrobial inhibition of Mycoplasma bovis isolates submitted to the Pennsylvania Animal Diagnostic Laboratory using flow cytometry and a broth microdilution method.

Marty K Soehnlen1, M Elaine Kunze, K Eranda Karunathilake, Brittnee M Henwood, Subhashinie Kariyawasam, David R Wolfgang, Bhushan M Jayarao.   

Abstract

Mycoplasma bovis is an important pathogen of cattle, causing mastitis, pneumonia, conjunctivitis, otitis, and arthritis. Currently there are only a few reports of sensitivity levels for M. bovis isolates from the United States. Mycoplasma bovis isolates submitted to the Pennsylvania Animal Diagnostic Laboratory between December 2007 and December 2008 (n = 192) were tested for antimicrobial susceptibility to enrofloxacin, erythromycin, florfenicol, spectinomycin, ceftiofur, tetracycline, and oxytetracycline using a broth microdilution method. The most effective antimicrobials against M. bovis determined by using the broth microdilution method were florfenicol, enrofloxacin, and tetracycline with minimum inhibitory concentration (MIC) ranges of 2-32 µg/ml, 0.1-3.2 µg/ml, and 0.05 to >12.8 µg/ml, respectively. Spectinomycin, oxytetracycline, and tetracycline showed a wide-ranging level of efficacy in isolate inhibition with broth microdilution with MIC ranges of 4 to >256 µg/ml, 0.05 to >12.8 µg/ml, and 0.05 to >12.8 µg/ml, respectively. A significant difference in the susceptibility levels between quarter milk and lung isolates was found for spectinomycin. When MIC values of a subset of the M. bovis isolates (n=12) were tested using a flow cytometric technique, the MIC ranges of enrofloxacin, spectinomycin, ceftiofur, erythromycin, tetracycline, oxytetracycline, and florfenicol ranges were 0.1-0.4 µg/ml, 4 to >256 µg/ml, >125 µg/ml, >3.2 µg/ml, <0.025 to >6.4 µg/ml, 0.8 to >12.8 µg/ml, and <2-4 µg/ml, respectively. Flow cytometry offers potential in clinical applications due to high-throughput capability, quick turnaround time, and the objective nature of interpreting results.
© 2011 The Author(s)

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908288     DOI: 10.1177/1040638711404155

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  14 in total

1.  16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Authors:  E Amram; I Mikula; C Schnee; R D Ayling; R A J Nicholas; R S Rosales; S Harrus; I Lysnyansky
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

Review 2.  Bovine Respiratory Disease: Conventional to Culture-Independent Approaches to Studying Antimicrobial Resistance in North America.

Authors:  Sara Andrés-Lasheras; Murray Jelinski; Rahat Zaheer; Tim A McAllister
Journal:  Antibiotics (Basel)       Date:  2022-04-05

3.  Suppression of antimicrobial peptide expression by ureaplasma species.

Authors:  Li Xiao; Donna M Crabb; Yuling Dai; Yuying Chen; Ken B Waites; T Prescott Atkinson
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

4.  Novel pegylated silver coated carbon nanotubes kill Salmonella but they are non-toxic to eukaryotic cells.

Authors:  Atul A Chaudhari; Shanese L Jasper; Ejovwoke Dosunmu; Michael E Miller; Robert D Arnold; Shree R Singh; Shreekumar Pillai
Journal:  J Nanobiotechnology       Date:  2015-03-22       Impact factor: 10.435

5.  Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.

Authors:  Anne V Gautier-Bouchardon; Séverine Ferré; Dominique Le Grand; Agnès Paoli; Emilie Gay; François Poumarat
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Lilla Fekete; Veronika Hrivnák; Tibor Magyar; Szilárd Jánosi; Nóra Schweitzer; Ibolya Turcsányi; László Makrai; Károly Erdélyi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2014-10-25       Impact factor: 2.741

7.  A novel covalent approach to bio-conjugate silver coated single walled carbon nanotubes with antimicrobial peptide.

Authors:  Atul A Chaudhari; D'andrea Ashmore; Subrata Deb Nath; Kunal Kate; Vida Dennis; Shree R Singh; Don R Owen; Chris Palazzo; Robert D Arnold; Michael E Miller; Shreekumar R Pillai
Journal:  J Nanobiotechnology       Date:  2016-07-13       Impact factor: 10.435

8.  Quantitative assessment of Mycoplasma hemadsorption activity by flow cytometry.

Authors:  Luis García-Morales; Luis González-González; Manuela Costa; Enrique Querol; Jaume Piñol
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 9.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

10.  Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China.

Authors:  Ling-Cong Kong; Duo Gao; Bo-Yan Jia; Zi Wang; Yun-Hang Gao; Zhi-Hua Pei; Shu-Ming Liu; Jiu-Qing Xin; Hong-Xia Ma
Journal:  J Vet Med Sci       Date:  2015-09-07       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.